Here are the 10-K annual reports from Medtronic plc (MDT) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow MDT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MDT filings page.
Medtronic plc provides a detailed overview of its global medical technology business, risks, and strategic priorities. The company operates across three main portfolios — Cardiovascular, Neuroscience, and Medical Surgical — offering devices from cardiac rhythm management and transcatheter valves to neuromodulation, surgical robotics, and acute care monitoring.
Medtronic highlights a major portfolio shift: its Diabetes Business is being separated into MiniMed Group, Inc., which completed an initial public offering in March 2026. The report also emphasizes heavy investment in R&D, expanded use of data, AI and automation, and a broad intellectual property base in an industry with intense competition and frequent litigation.
The company underscores human capital as a key asset, with over 95,000 employees, strong pay-equity metrics, and extensive learning programs. It also devotes substantial discussion to regulatory, reimbursement, data-privacy, trade, and environmental frameworks that shape how its products are developed, approved, manufactured, and paid for worldwide, including EU MDR, GDPR, and evolving AI regulation.
Medtronic filed its FY2025 10-K report, detailing operations across four major segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. The company maintains a strong international presence with significant operations in both US and international markets.
Key operational highlights include:
- Strategic focus on enterprise excellence and simplification restructuring programs
- Continued investment in research and development across all segments
- Notable divestiture of the Ventilator Product Line in February 2024
- Completion of the Renal Care Solutions/Mozarc transaction in April 2023
Financial structure includes various senior notes due between 2025-2053 with interest rates ranging from 0% to 4.15%. The company maintains a diversified debt portfolio in multiple currencies (USD, EUR, JPY). Significant emphasis on fair value measurements and risk management, particularly in Level 3 assets including revenue and product development milestones.